Atrium Medical Corporation
10
1
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
30.0%
3 terminated/withdrawn out of 10 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
67%
4 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Advanta VXT and Flixene PMCF Registry
Role: lead
Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
Role: lead
Atrium iCAST Iliac Stent Pivotal Study
Role: lead
Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta
Role: lead
The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries
Role: lead
Comparative Effectiveness Multicenter Trial for Adhesion Characteristics of Ventral Hernia Repair Mesh
Role: collaborator
Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia
Role: collaborator
The INFUSE - Anterior Myocardial Infarction (AMI) Study
Role: lead
ClearWay™ RX Registry Trial
Role: lead
COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms (CONFIRM 1)
Role: lead
All 10 trials loaded